Abstract | BACKGROUND: OBJECTIVE: This review discusses how mutations occur that result in elevated expression the PI3K/PTEN/Akt/mTOR pathway and lead to malignant transformation, and how effective targeting of this pathway may result in suppression of abnormal growth of cancer cells. METHODS: We searched the literature for articles which dealt with altered expression of this pathway in various cancers including: hematopoietic, melanoma, non-small cell lung, pancreatic, endometrial and ovarian, breast, prostate and hepatocellular. RESULTS/CONCLUSIONS: The PI3K/PTEN/Akt/mTOR pathway is frequently aberrantly regulated in various cancers and targeting this pathway with small molecule inhibitors and may result in novel, more effective anticancer therapies.
|
Authors | Linda S Steelman, Kristin M Stadelman, William H Chappell, Stefan Horn, Jörg Bäsecke, Melchiorre Cervello, Ferdinando Nicoletti, Massimo Libra, Franca Stivala, Alberto M Martelli, James A McCubrey |
Journal | Expert opinion on therapeutic targets
(Expert Opin Ther Targets)
Vol. 12
Issue 9
Pg. 1139-65
(Sep 2008)
ISSN: 1744-7631 [Electronic] England |
PMID | 18694380
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Antineoplastic Agents
- Proto-Oncogene Proteins c-akt
|
Topics |
- Animals
- Antineoplastic Agents
(pharmacology)
- Humans
- Mice
- Neoplasms
(drug therapy)
- Proto-Oncogene Proteins c-akt
(antagonists & inhibitors)
|